Logo Logo Logo Logo Logo
  • FOR PROVIDERS
  • FOR PATIENTS
  • WHY NEXALIN
  • TIMELINE
  • Investors
  • Contact Us
  • FOR PROVIDERS
  • FOR PATIENTS
  • WHY NEXALIN
  • TIMELINE
  • Investors
  • Contact Us
  • News & Events
    • Press Release
    • IR Calendar
    • Email Alerts
  • Company Information
    • Presentations
    • Board of Directors
    • FAQs
  • Financial Information
    • Financial Results
    • Balance Sheet
    • Income Statement
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Documents
Menu
  • News & Events
    • Press Release
    • IR Calendar
    • Email Alerts
  • Company Information
    • Presentations
    • Board of Directors
    • FAQs
  • Financial Information
    • Financial Results
    • Balance Sheet
    • Income Statement
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Documents

news & events

  • Press Release
  • IR Calendar
  • Email Alerts
Menu
  • Press Release
  • IR Calendar
  • Email Alerts

press release

  • Investor Relations
  • June 1, 2023

Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region

Read More
  • Investor Relations
  • March 27, 2023

Nexalin Technology Provides 2022 Year-End Business Update

Read More
  • Investor Relations
  • January 24, 2023

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

Read More
  • Investor Relations
  • January 5, 2023

Nexalin Technology CEO Provides Letter to Shareholders

Read More
  • Investor Relations
  • November 14, 2022

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

Read More
  • Investor Relations
  • September 20, 2022

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

Read More
Load More
TREATMENTS
  • ANXIETY
  • INSOMNIA
IMPORTANT LINKS
  • Contact Us
RECEIVE THE LATEST NEWS

© 2021 Nexalin Technology All Rights Reserved.